Kansas City, KS. – (January 2017) KCAS Bioanalytical and Biomarker Services, a leading functional service
contract research organization (CRO) is pleased to announce the expansion of their executive leadership
team. KCAS welcomes Mr. Buddy Worrell to the position of Vice President of Marketing and Sales.
“The addition of Buddy Worrell to our leadership team is one more step towards setting the stage for
KCAS’ evolution as a service provider. We are committed to identifying, attracting and growing the
talent we need to become a leading provider of Bioanalytical services.” stated John Bucksath, CEO.
Mr. Worrell joins KCAS with 30+ years of marketing and sales expertise. He has worked with several
CROs and brings with him in depth knowledge of pharmaceutical business development practices,
forecasting and marketing. Retiring in 2012, Buddy consulted and served on advisory councils. However,
having the opportunity to step back into a full-time role to coach a team of professionals through a highgrowth
period was irresistible.
“The prospect of working with John Bucksath and the fine folks at KCAS was enough to draw me out of
retirement on the North Carolina coast. The talented Marketing and Sales team has been generous and
welcoming as I lay out my vision of the future for our department. We have an incredible track record
and I have no doubts as to the success at KCAS.” stated Buddy Worrell, Vice President of Marketing and
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 37+ years of bioanalytical
expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity,
and biomarker analysis operating a variety of equipment platforms to service a wide range of
therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at
the company to provide clients of all sizes with expertise in robust assay development, validation, and
sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and
clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have
undergone 16 FDA inspections. Learn more at: www.kcasbio.com
To see more about KCAS, please click here